Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Redde Northgate to change name to Zigup

(Sharecast News) - Redde Northgate is seeking approval to change its name to Zigup, the mobility specialist confirmed on Friday. The FTSE 250 firm, which specialises in commercial vehicles, said the proposed name change was allied to its refreshed strategic framework and a recent UK and Ireland-focused management reorganisation.

It continued: "The board believes that a more modern brand and name reflecting these changes will help shift the narrative with our stakeholders towards the strategic director of travel we set out.

"This is aligned to our updated purpose, 'to keep customers moving, smarter'."

It noted there would be no change to its "well-recognised" operational brands, however, "which have meaningful market profiles in their specialist areas".

The company, which was created in 2020 after motor insurance services firm Redde merged with fleet hire specialist Northgate, will now seek shareholder approval for the change at a general meeting on 15 May.

Should the proposed change secure investor backing, the roll-out of the new brand will get underway on 20 May.

Share this article

Related Sharecast Articles

Goldman Sachs downgrades SSP to 'sell', prefers WH Smith
(Sharecast News) - Goldman Sachs downgraded SSP on Monday to 'sell' from 'neutral' "on a relative basis" as it took a look at European travel concessions.
UBS to book $900m provision over Greensill supply financing funds
(Sharecast News) - Swiss banking giant UBS announced on Monday that it expected to book a provision of about $900m related to Credit Suisse's funds, tied to the collapsed supply chain financing firm Greensill Capital.
Citi downgrades European equities to 'neutral'
(Sharecast News) - Citi downgraded its stance on European equities on Monday to 'neutral' from 'overweight' as it said near-term risks have increased, with markets narrowing and political uncertainty taking centre stage.
Hutchmed publishes positive sovleplenib trial results
(Sharecast News) - Hutchmed China announced the publication of positive results from its phase three 'ESLIM-01' trial of sovleplenib in the Lancet Haematology.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.